We will closely watch this dynamic to continue to assess whether the end of shortage allows Novo the opportunity to recapture share in the US obesity market," wrote BMO analyst Evan Seigerman in a ...

But those effects have to be proven in clinical trials. In a research note Monday, BMO analyst Evan Seigerman said "all-in we're positive on the deal" for AbbVie. He said the company's entrance ...

According to Evan David Seigerman of BMO Capital Markets, the results leave the company still searching for the next big breakthrough after semaglutide, the active ingredient in Ozempic and Wegovy.

setting," said BMO Capital Markets analyst Evan Seigerman. Future treatments will need to show benefits such as fewer side effects and improved heart health, he added. Veru's drug helped patients ...

(Reuters) - About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to ...

setting,” said BMO Capital Markets analyst Evan Seigerman. Future treatments will need to show benefits such as fewer side effects and improved heart health, he added. Veru’s drug helped ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...